|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways.
|
30405800 |
2018 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The cyclin-dependent kinase inhibitor 1 (CDKN2B or p15(INK4B) ) gene lies adjacent to the tumor suppressor gene, cyclin-dependent kinase inhibitor 2 (CDKN2A), and is frequently mutated and deleted in a wide variety of tumors, including MM.
|
25382971 |
2014 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
|
12200702 |
2002 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
|
27363682 |
2016 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Selective methylation was found in 19% for p16(INK4a), 36% for p15(INK4b), and 6.5% for both genes in MGUS, and frequencies were similar in MM suggesting that methylation of these genes is an early event, not associated with transition from MGUS to MM. p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM.
|
11418489 |
2001 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To examine the function of p18 as a putative tumor suppressor in myeloma cells, a zinc-inducible p18 construct was stably transfected into KMS12, a MM cell line with biallelic p18 and monoallelic p16 deletions as well as cyclin D1 overexpression.
|
11840272 |
2002 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that ANRIL may be involved in melphalan-mediated apoptosis via down-regulating p14ARF and subsequent p53, and that the rs2151280 polymorphism may be a potential prognostic biomarker for relapse in melphalan-treated MM patients.
|
28150872 |
2017 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32-2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76-0.85).
|
26099684 |
2015 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that inactivation of the p16 gene by methylation may be associated with decreased growth control and the development of PCL in a subset of patients with MM.
|
9815612 |
1997 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have tested whether CpG methylation of both CDKN2A and TP73 occurs in 45 individuals with multiple myeloma (24 male and 21 female, mean age 66.4 years) and in 4 patients (2 male and 2 female, mean age 61.7 years) with Waldenström's macroglobulinemia.
|
19423161 |
2009 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
As regards p16 methylation, we confirmed a high prevalence of p16 methylation (40%) in patients affected by MM and demonstrated that MTHFR 677CC is associated with a higher prevalence of p16 hypermethylation.
|
16541270 |
2006 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM.
|
16840723 |
2007 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, p16 methylation seems to have no correlation with angiogenesis and VEGF expression, neither with overall and event-free survival in MM patients.
|
15863274 |
2005 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might be of prognostic significance. p14 and Apaf-1 were not methylated in MM.
|
17557868 |
2007 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
This data favours the importance of p16 methylation on cell cycle regulation in multiple myeloma.
|
16166769 |
2005 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
LHGDN |
These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle regulation of multiple myeloma tumour cells, and thus in the clinical outcome of the disease.
|
12199782 |
2002 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings suggest methylation of TP73, ARF, p15 INK4B , and p16 INK4A as early events in the pathogenesis and development of plasma cell disorders; meanwhile, SOCS-1 methylation would be an important step in the clonal evolution from MGUS to MM.
|
19727727 |
2010 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This is the second case report of germline mutation of CDKN2A being associated with myeloma.CDKN2A is a stabiliser of p53.
|
29110637 |
2017 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
It is possible that hypermethylation of the p16INK4A gene promoter contributes to progression to aggressive MM from indolent PCD, especially to extra-PC development.
|
11243384 |
2001 |
|
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have analyzed the methylation pattern of exon E1alpha of the p16 gene in 101 untreated MM and five primary plasma cell leukemias (PCL).
|
10637494 |
2000 |
|
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.
|
17043023 |
2006 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated the methylation status of p16 and its association with common cytogenetic changes, clinicolaboratory findings, and survival in MM.
|
20721556 |
2011 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
In 32 cases of multiple myeloma and 19 cases of MGUS, significantly more frequent methylation of p16 (p = 0.001), SHP1 (p< or =0.001) and E-cadherin (p< or =0.001) genes was found in multiple myeloma than in MGUS.
|
17213358 |
2007 |
|
Multiple Myeloma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
The current meta-analysis confirms and reinforces existing findings that p15 (INK4b) and p16 (INK4a) promoter methylation may be closely implicated in the pathogenesis of MM.
|
24908414 |
2014 |
|
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, hypermethylation was observed in 75% for p16 and 67% for p15 in our group of MM patients.
|
9116295 |
1997 |